RELIEF THERAPEUTICS HOLDINGS AG (NASDAQ:RLFTF) RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders

Transparency directive : regulatory news

26/05/2023 07:00

Relief Therapeutics Holding SA / Key word(s): AGMEGM
RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders

26-May-2023 / 07:00 CET/CEST
Release of an ad hoc announcement pursuant to Art. 53 LR
The issuer is solely responsible for the content of this announcement.

RELIEF THERAPEUTICS Holding SA Announces Notice of Annual General Meeting of Shareholders

GENEVA (May 26, 2023) – RELIEF THERAPEUTICS Holding SA (SIX: RLF, OTCQB: RLFFD, RLFTD) (Relief Therapeutics, or the Company), a biopharmaceutical company committed to delivering innovative treatment options with the potential for transformative outcomes to benefit those suffering from select specialty and rare diseases, today announced the Annual General Meeting (AGM) of shareholders will take place Tues., June 20, 2023 at 9 a.m. CEST at avenue de Sécheron 15 in Geneva, near the Relief Therapeutics offices.


The agenda includes the discussion and adoption of the annual accounts for the 2022 financial year, appropriation of the result, the discharge of the board of directors and executive committee for their duties performed in 2022, extension of the duration of the Company's capital band and an increase of the conditional share capital, several proposed amendments and additions to the articles of association related to the new Swiss corporate law, the compensation of the members of the board of directors and of the executive committee as well as the re-election of existing members of the board of directors, the chairman of the board of directors, the nomination and compensation committee, independent voting rights representative and auditors.

The formal notice of convocation of the AGM, including information on attending the meeting in person or by proxy, requirements for notification and registration for the meeting, regarding the e-voting system as well as all ancillary documents relevant for the meeting, will be mailed Tues., May 30, 2023 to registered shareholders. The full agenda is available on the Relief Therapeutics website.


Relief Therapeutics is a commercial-stage biopharmaceutical company committed to advancing treatment paradigms and delivering improvements in efficacy, safety and convenience to benefit the lives of patients living with select specialty and rare diseases. Relief Therapeutics' portfolio offers a balanced mix of marketed, revenue-generating products, our proprietary, globally patented Physiomimic™ and TEHCLO™ drug delivery platform technologies and a highly targeted clinical development pipeline consisting of risk-mitigated assets focused in three core therapeutic areas: rare metabolic disorders, rare skin diseases and rare respiratory diseases. In addition, Relief Therapeutics is commercializing several legacy products via licensing and distribution partners. Relief Therapeutics' mission is to provide therapeutic relief to those suffering from rare diseases and is being advanced by an international team of well-established, experienced biopharma industry leaders with extensive research, development and rare disease expertise. Relief Therapeutics is headquartered in Geneva, with additional offices in Balerna, Switzerland, Offenbach am Main, Germany and Monza, Italy. Relief Therapeutics is listed on the SIX Swiss Exchange under the symbol RLF and quoted in the U.S. on OTCQB under the symbols RLFFD and RLFTD. For more information, please visit our website www.relieftherapeutics.com or follow Relief Therapeutics on LinkedIn and Twitter.


Catherine Day
Vice President, Investor Relations & Communications

This press release contains forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties, and other factors, which could cause the actual results, financial condition, performance or achievements of Relief Therapeutics to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. A number of factors including those described in Relief Therapeutics' filings with the SIX Swiss Exchange and the U.S. Securities and Exchange Commission (SEC) could adversely affect Relief Therapeutics. Copies of Relief Therapeutics' filings with the SEC are available on the SEC EDGAR database at www.sec.gov. Relief Therapeutics does not undertake any obligation to update the information contained herein, which speaks only as of this date.

Additional features:

File: Ad hoc release

End of Inside Information
Language: English
Company: Relief Therapeutics Holding SA
Avenue de Secheron 15
1202 Geneva
Phone: +41 22 545 11 16
E-mail: contact@relieftherapeutics.com
Internet: https://relieftherapeutics.com
ISIN: CH0100191136
Valor: 10019113
Listed: SIX Swiss Exchange
EQS News ID: 1642377

End of Announcement EQS News Service

1642377  26-May-2023 CET/CEST


Other stories

28/02/2024 20:15
28/02/2024 19:58
28/02/2024 19:51
28/02/2024 15:34
28/02/2024 14:36
28/02/2024 14:22
28/02/2024 18:29
28/02/2024 18:04
28/02/2024 16:04
28/02/2024 20:40
28/02/2024 21:04
28/02/2024 16:05
28/02/2024 06:00
28/02/2024 20:33
28/02/2024 19:36
28/02/2024 16:51
28/02/2024 10:25
28/02/2024 18:49
28/02/2024 09:58
27/02/2024 13:30
28/02/2024 17:17
28/02/2024 11:41
28/02/2024 15:31
28/02/2024 15:32
28/02/2024 19:14
28/02/2024 16:36
28/02/2024 20:09
28/02/2024 20:08
28/02/2024 19:00
28/02/2024 20:18
28/02/2024 20:23
28/02/2024 09:51
27/02/2024 16:35
26/02/2024 21:44
28/02/2024 05:12
28/02/2024 17:32
27/02/2024 15:15
28/02/2024 09:57